Page 1

> Adicet Bio Adicet Reports Third Quarter 2021 Financial Results and Provides Business Updates November 10 , 2021 • On track to report top - line safety and tolerability data from ADI - 001 Phase 1 study in Non - Hodgkin's Lymphoma ( NHL ) by year end • Announced collaboration with Twist Bioscience to accelerate discovery of gamma delta T cell cancer therapeutics and expand pipeline MENLO PARK , Calif . and BOSTON , Nov. 10 , 2021 ( GLOBE NEWSWIRE ) -- Adicet Bio , Inc. ( Nasdaq : ACET ) , a biotechnology company discovering and developing first - in - class allogeneic gamma delta T cell therapies for cancer and other diseases , today reported operational highlights and financial results for the third quarter ended September 30 , 2021 . " Over the third quarter , Adicet has made steady progress in advancing the first - in - human Phase 1 trial of our lead asset , ADI - 001 , in NHL , and we look forward to sharing preliminary data from this trial by the end of the year , " said Chen Schor , President and Chief Executive Officer of Adicet Bio . " In addition to this key upcoming milestone , we're also excited about our collaboration with Twist Bioscience that is focused on further expanding our internal pipeline of next - generation off - the - shelf , CAR - T therapies for the treatment of cancer and other diseases . " Third Quarter & Recent Business Updates : • ADI - 001 Phase 1 Clinical Trial Enrolling in Dose Level 2. The dose - escalation portion of the Phase 1 study of ADI - 001 for patients with B Cell Malignancies relapsed or refractory after at least two prior regimens has completed dosing in Dose Level 1. Enrollment is ongoing for Dose Level 2. The Company expects to report interim clinical data from the initial dose - escalation portion of the study by the end of 2021 . • Reported Trials in Progress Poster Presentation at ASH . In November , Adicet announced that Sattva S. Neelapu , MD from UT MD Anderson Cancer center will present a Trials in Progress Poster for ADI - 001 at the 63rd American Society of Hematology ( ASH ) Annual Meeting and Exposition on December 12 from 6:00 pm to 8:00 pm ET . The abstract will also be published online in the November supplemental issue of Blood . • Preclinical Data to be Presented at the SITC 36th Annual Meeting . In October , Adicet announced that it will present preclinical data from its allogeneic gamma delta T cell platform in the form of a poster presentation at the Society for Immunotherapy of Cancer ( SITC ) 36th Annual Meeting being held November 10-14 , 2021 . • Entered Collaboration with Twist Bioscience to Accelerate Discovery of Gamma Delta T Cell Cancer Therapeutics . In September , Adicet announced that it entered into a collaboration with Twist Bioscience Corporation ( Twist ) to accelerate the discovery of gamma delta T cell therapies against five undisclosed targets . Adicet will leverage Twist's proprietary antibody discovery capabilities to support the development of unique chimeric antigen receptors ( CARS ) used in the generation of novel gamma delta CAR - T cell products , further enhancing its pipeline in cancer and other diseases . Financial Results for Third Quarter 2021 : • Research and Development ( R & D ) Expenses : R & D expenses were $ 11.9 million for the three months ended September 30 , 2021 , compared to $ 8.9 million during the same period in 2020. The $ 3.0 million increase is primarily driven by an increase of $ 1.3 million incurred for contract research organizations , and consultant costs related to ramping up of clinical development activities related to our first product candidate , ADI - 001 and other externally sponsored research expenses , an increase of $ 1.4 million in facility and other expenses and an increase of $ 0.4 million of contract manufacturing organization costs . These increases were partially offset by decreases in lab materials and supplies of $ 0.1 million and payroll and personnel expenses of $ 0.1 million . Payroll and personnel expenses for the three months ended September 30 , 2021 , includes $ 0.8 million of non - cash stock - based compensation expense compared to $ 1.0 million during the same period in 2020 . • General and Administrative ( G & A ) Expenses : G & A expenses were $ 5.2 million for the three months ended September 30 , 2021 , compared to $ 7.7 million during the same period in 2020. The $ 2.5 million decrease is primarily driven by a decrease in professional fees of $ 1.7 million , which includes a $ 1.9 million decrease related to legal and audit fees incurred due to our reverse merger in 2020 offset by $ 0.2 million increase in other administrative costs . In addition , there was also a decrease of $ 0.8 million related to payroll and personnel expenses , primarily related to consultant fees of $ 0.7